Syngene International Ltd. (NSE: SYNGENE), a prominent global contract research, development, and manufacturing organization (CRDMO), has announced the launch of a new protein production platform. This innovative platform integrates cell line and transposon-based technology, licensed from the Swiss biotech services company ExcellGene, with Syngene’s own sophisticated clone selection and development processes. This integration promises a […]
Syngene International has announced the conclusion of its acquisition of a multi-modal biologics manufacturing facility, known as ‘Unit 3’, from Stelis Biopharma Ltd. The deal was finalized at a revised gross value of Rs 617 crores, adjusted from the initial value of Rs 702 crores. Revised Deal Terms Reflect Equipment Retention The reduction in the […]
Pharma manufacturing services company Syngene International has unveiled plans to acquire Unit 3 biologics manufacturing facility located in Bangalore, India from Stelis Biopharma Limited (SBL). The agreement will result in an additional 20,000 liters of installed biologics drug substance manufacturing capacity for Syngene, with the possibility of doubling this figure in the future. The facility […]
Syngene International said that it has incorporated a fully-owned subsidiary called Syngene Manufacturing Solutions Limited (SMSL). Syngene Manufacturing Solutions will be involved in the manufacturing of pharmaceutical, biological, and biopharmaceutical products of any type. Based in India, Syngene International is a research, development, and manufacturing organization. The company caters to a variety of industrial sectors […]
Syngene International Limited has signed a 10-year biologics manufacturing agreement with American animal health company Zoetis for manufacturing the drug substance for Librela (bedinvetmab), a first in class monoclonal antibody used for the treatment of osteoarthritis in dogs. The Indian research, development, and manufacturing services company has been collaborating with Zoetis since 2011. During this […]
